Replies to post #422961 on Amarin Corp Plc (AMRN)

[ORBAPU]

As I posted earlier, everyone currently has plausible deniability. If the specific indication is on the label, that goes away.

As such, generics will fight to their last breath to prevent any such thing. Insurance companies, PBM’s, pharmacies, and doctors will join them!

[JRoon71]

Dave, if gV is considered bioequivalent, I'm not sure how that would ever be the case.

However, one interesting thing to note, is that BP's, from time-to-time, will send letters to medical practices, reminding them about prescribing generic products for off-label indications when there is a branded, patented product covering said indication. I'm not sure if Amarin has ever done this. I assume not. But it seems like something they SHOULD do. I recall seeing a letter sent by Pfizer like this for one of their drugs. I found it online. I should try to dig that up.

JRoon,
Suppose Hikma had the correct indication on the Label, Trigs only, and a doctor prescibed generic V to a CVD patient.
If the patient then had a heart attack, wouldn't the doctor be liable for malpractice? Would this fear keep the docs precribing V?
Dave